Literature DB >> 7912930

Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1.

A F Kavanaugh1, L S Davis, L A Nichols, S H Norris, R Rothlein, L A Scharschmidt, P E Lipsky.   

Abstract

OBJECTIVE: To assess the safety and efficacy of a monoclonal antibody (MAb) to intercellular adhesion molecule 1 (ICAM-1; CD54) in rheumatoid arthritis (RA).
METHODS: A phase I/II, open-label, dose-escalation study of 32 patients.
RESULTS: During treatment, a peripheral CD3+/CD4+ lymphocytosis was noted, and several patients demonstrated transient cutaneous anergy, which suggests that therapy modified T cell recirculation. Thirteen of the 23 patients who received 5 days of treatment demonstrated clinical improvement through day 29, and 9 of 23 through day 60. Adverse effects were minor and transient.
CONCLUSION: Anti-ICAM-1 MAb therapy was well tolerated, resulted in a transient alteration in T lymphocyte recirculation, and effected clinical improvement in some RA patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7912930     DOI: 10.1002/art.1780370703

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  49 in total

Review 1.  Biologic therapies in rheumatoid arthritis.

Authors:  K J Bulpitt
Journal:  Curr Rheumatol Rep       Date:  1999-12       Impact factor: 4.592

2.  Comparison of soluble adhesion molecules in juvenile idiopathic arthritis between the active and remission stages.

Authors:  C-Y Chen; C-H Tsao; L-S Ou; M-H Yang; M-L Kuo; J-L Huang
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

Review 3.  New therapies in development for autoimmune diseases: their rationale for combination treatment.

Authors:  V Strand
Journal:  Springer Semin Immunopathol       Date:  2001

4.  Vascular cell adhesion molecule-1 (VCAM-1) blockade in collagen-induced arthritis reduces joint involvement and alters B cell trafficking.

Authors:  R A Carter; I K Campbell; K L O'Donnel; I P Wicks
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

Review 5.  Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention.

Authors:  J Panés; M Perry; D N Granger
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

6.  125I-labeled gold nanorods for targeted imaging of inflammation.

Authors:  Xia Shao; Huanan Zhang; Justin R Rajian; David L Chamberland; Phillip S Sherman; Carole A Quesada; Alisa E Koch; Nicholas A Kotov; Xueding Wang
Journal:  ACS Nano       Date:  2011-10-27       Impact factor: 15.881

7.  Nuclear translocation of p65 NF-kappaB is sufficient for VCAM-1, but not ICAM-1, expression in TNF-stimulated smooth muscle cells: Differential requirement for PARP-1 expression and interaction.

Authors:  Mourad Zerfaoui; Yasuhiro Suzuki; Amarjit S Naura; Chetan P Hans; Charles Nichols; A Hamid Boulares
Journal:  Cell Signal       Date:  2007-10-12       Impact factor: 4.315

8.  NF-κB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-κB in immune-mediated diseases.

Authors:  Bettina Sehnert; Harald Burkhardt; Johannes T Wessels; Agnes Schröder; Michael J May; Dietmar Vestweber; Jochen Zwerina; Klaus Warnatz; Falk Nimmerjahn; Georg Schett; Stefan Dübel; Reinhard Edmund Voll
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-23       Impact factor: 11.205

Review 9.  Adhesion molecules in rheumatoid arthritis.

Authors:  N Oppenheimer-Marks; P E Lipsky
Journal:  Springer Semin Immunopathol       Date:  1998

10.  Soluble cell adhesion molecules and von Willebrand factor in children with Kawasaki disease.

Authors:  M C Nash; V Shah; M J Dillon
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.